Menu

no photo of Erdal Cavusoglu

Erdal Cavusoglu, MD

Professor of Medicine
Cardiology

Education and Training:
Fellowship:
Interventional Cardiology, Mount Sinai Medical Center, New York, NY 1999-2001
Cardiology, Albert Einstein College of Medicine, Bronx, NY 1992-95
Residency:
Columbia Presbyterian Medical Center, New York, NY 1990-92
Internship:
Beth Israel Hospital (Harvard Medical School), Boston, MA 1989-90
Medical School:
Mount Sinai School of Medicine, New York, NY 1989
Grant Support
National Institutes of Health
Type of Award: Exploratory/Developmental Research Grant Program (Parent R21)
Project Name: Plasma F11R and Cardiovascular Outcomes in Patients with Coronary Artery Disease
Role: Principal Investigator
Funding Agency: National Heart, Lung and Blood Institute
Grant Number: 1R21HL098661-01
Period of Support: 03/01/2010 - 02/29/2012
American Heart Association
Type of Award: Grant-in-Aid
Project Name: Endogenous Erythropoietin and Outcome in Coronary Artery Disease
Role: Principal Investigator
Funding Agency: American Heart Association (Founders Affiliate)
Application Number: 10GRNT3700003
Period of Support: 07/01/2010 - 06/30/2013
National Institutes of Health
Type of Award: Exploratory/Developmental Research Grant Program (Parent R21)
Project Name: The Role of Autoimmune Natural IgM in Human Myocardial Infarction
Role: Co-Principal Investigator (Principal Investigator Ming Zhang, M.D., PhD)
Funding Agency: National Heart, Lung and Blood Institute
Grant Number: 1R21HL088527-01A1
Period of Support: 07/01/2009 - 06/30/2011
National Institutes of Health National Research Service Award
(NRSA) Postdoctoral Fellowship Training Grant Recipient
Project Name: Regulation and Biologic Role of SM-20 in Smooth Muscle
Principal Investigator: Erdal Cavusoglu, MD
Fellowship Number: 1 F32 HL09354-01
Funding Agency: NHLBI
Area of Training: Molecular Biology
Inclusive Dates of Approval: July 1995 - June 1998
  • Cavusoglu E, Marmur JD, Kassotis JT, Yanamadala S, Chopra V, Eng C. Usefulness of Plasma Matrix Metalloproteinase-3 Levels to Predict Myocardial Infarction in Men with and without Acute Coronary Syndrome Am J Cardiol. March 2016. Manuscript in Press
  • Cavusoglu E, Marmur JD, Yanamadala S, Chopra V, Hegde S, Nazli A, Singh KP, Zhang M, Eng C. Elevated baseline plasma IL-8 levels are an independent predictor of long-term all-cause mortality in patients with acute coronary syndrome. Atherosclerosis. 2015 Oct;242(2):589-94.
  • Cavusoglu E, Marmur JD, Chhabra S, Hojjati MR, Yanamadala S, Chopra V, Eng C, Jiang XC. Elevated baseline plasma phospholipid protein (PLTP) levels are an independent predictor of long-term all-cause mortality in patients with diabetes mellitus and known or suspected coronary artery disease. Atherosclerosis. 2015 Apr;239(2):503-8.
  • Cavusoglu E, Marmur JD, Hegde S, Yanamadala S, Batuman OA, Chopra V, Ay G, Eng C. Relation of baseline plasma MMP-1 levels to long-term all-cause mortality in patients with known or suspected coronary artery disease referred for coronary angiography. Atherosclerosis. 2015 Mar;239(1):268-75.
  • Zhang M, Hou YJ, Cavusoglu E, Lee DC, Steffensen R, Yang L, Bashari D, Villamil J, Moussa M, Fernaine G, Jensenius JC, Marmur JD, Ko W, Shevde K. MASP-2 activation is involved in ischemia-related necrotic myocardial injury in humans. Int J Cardiol. 2013 Jun 20; 166(2):499-504.
  • Cavusoglu E, Marmur JD, Hojjati MR, Chopra V, Butala M, Subnani R, Huda MS, Yanamadala S, Ruwende C, Eng C, Pinsky DJ. Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome. Am J Med. 2011 Aug;124(8):724-30.
  • Accompanying Editorial: Alpert JS. Biomarkers in clinical practice. Am J Med. 2011 Aug;124(8):677-8.
  • Azari BM, Marmur JD, Salifu MO, Cavusoglu E, Ehrlich YH, Kornecki E, Babinska A. Silencing of the F11R gene reveals a role for F11R/JAM-A in the migration of inflamed vascular smooth muscle cells and in atherosclerosis. Atherosclerosis. 2010 Sep;212(1):197-205.
  • Poludasu S, Cavusoglu E, Khan W, Marmur JD. Neutrophil to lymphocyte ratio as a predictor of long-term mortality in African Americans undergoing percutaneous coronary intervention. Clin Cardiol. 2009 Dec;32(12):E6-E10.
  • Cavusoglu E, Ruwende C, Chopra V, Poludasu S, Yanamadala S, Frishman WH, Eng C, Pinsky DJ, Marmur JD. Relation of Baseline Plasma ADMA Levels to Cardiovascular Morbidity and Mortality at Two Years in Men with Diabetes Mellitus Referred for Coronary Angiography. Atherosclerosis. 2010 May;210(1):226-31.
  • Poludasu S, Marmur JD, Weedon J, Khan W, Cavusoglu E. Red Cell Distribution Width (RDW) as a Predictor of Long-term Mortality in Patients Undergoing Percutaneous Coronary Intervention. Thromb Haemost. 2009 Sep;102(3):581-7.
  • Cavusoglu E, Marmur JD, Chhabra S, Chopra V, Eng C, Jiang XC. Relation of Baseline Plasma Phospholipid Transfer Protein (PLTP) Activity to Left Ventricular Systolic Dysfunction in Patients Referred for Coronary Angiography. Atherosclerosis. 2009 Nov;207(1):261-5.
Case Reports
  • Manjappa R, Agarwal A, Cavusoglu E. Very Late Stent Thrombosis. A Case Report. Very late bare-metal stent thrombosis. A case report and review of the literature. J Invasive Cardiol. 2006 Jul;18(7):E203-6.
  • Mungee S, Lapin R, Cavusoglu E, Clark LT, and Marmur JD. Percutaneous Coronary Percutaneous Coronary Intervention in a Patient with Congenital Factor XI Deficiency and Acquired Inhibitor. Cardiology 2006 Jun 22;107(1):69-72.
  • Castillo R, Cavusoglu E. Twiddler's Syndrome: An Interesting Cause of Pacemaker Failure. Cardiology 2006;105(2):119-21.
  • Lingegowda US, Marmur JD, Cavusoglu E. Catheter-induced spasm of the left main coronary artery due to anatomic "kinking" in its course. J Invasive Cardiol. 2005 Mar;17(3):192-4.
Review Articles
  • Kokolis S, Clark LT, Cavusoglu E, Marmur JD. Direct thrombin inhibitor use during percutaneous coronary intervention. Journal of Cardiovascular Pharmacology 2005 Mar;45(3):270-9.
  • Cavusoglu E, Chhabra S, Marmur JD, Kini A, Sharma SK. The prevention of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention. Minerva Cardioangiol. 2004 Oct;52(5):419-32.
  • Cavusoglu E, Kini AS, Marmur JD, Sharma SK. Current status of rotational atherectomy. Catheter Cardiovasc Interv. 2004 Aug;62(4):485-98.
  • Kokolis S, Cavusoglu E, Clark LT, Marmur JD. Anticoagulation strategies for patients undergoing percutaneous coronary intervention: unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors. Prog Cardiovasc Dis. 2004 May-Jun;46(6):506-23.
  • Chopra V, Marmur JD, Cavusoglu E. The role of clopidogrel in the management of patients with ischemic heart disease. Cardiovasc Drugs Ther. 2003 Sep-Nov;17(5-6):467-77.
  • Cavusoglu E. The use of clopidogrel in patients with coronary artery disease. Anadolu Kardiyol Derg. 2004 Mar;4(1):63-72.
  • Anand SX, Viles-Gonzalez JF, Badimon JJ, Cavusoglu E, Marmur JD. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost. 2003 Sep;90(3):377-84.
  • Cavusoglu E, Cheng J, Bhatt R, Kunamneni PB, Marmur JD, and Eng C. Clopidogrel in the management of ischemic heart disease. Heart Dis. 2003 Mar-Apr;5(2):144-52.
  • Cavusoglu E. Plasma homocysteine, coronary risk factors and serum nitrite in coronary artery disease and vascular syndrome x. Editorial. Anadolu Kardiyol Derg 2003;3:35-37.
  • Soma VR, Cavusoglu E, Vidhun R, Frishman WH, Sharma SK. Contrast-associated nephropathy. Heart Dis. 2002;4:372-379.
  • Marmur JD, Cavusoglu E. The Use of the Glycoprotein IIb/IIIa Receptor Antagonists During Percutaneous Coronary Intervention. J Interv Cardiol. 2002;15(1): 71-84.
  • Cavusoglu E, Sharma SK, Frishman WH. Unstable Angina Pectoris and Non-Q-Wave Myocardial Infarction Heart Dis. 2001;3(2): 116-130.
Book Chapters
  • Cavusoglu E. The Effects of Antiplatelet, Antithrombotic and Fibrinolytic Agents on Circulating Biomarkers. In: Freedman JE, Loscalzo J (editors): New Therapeutic Agents in Thrombosis and Thrombolysis. Informa Healthcare, 2009
  • Frishman WH, Cavusoglu E, Zonszein J. Magnesium, Potassium, and Calcium as Potential Cardiovascular Disease Therapies. In: Frishman WH, Sonnenblick EH (editors): Cardiovascular Pharmacotherapeutics. McGraw-Hill, 1997
  • Frishman WH, Cavusoglu E. b-Adrenergic Blockers and Their Role in the Therapy of Arrhythmias. In: Podrid PJ, Kowey PR (editors): Cardiac Arrhythmias - Mechanisms, Diagnosis and Management. Williams and Wilkins, Baltimore 1994